Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism
- PMID: 33609962
- DOI: 10.1016/j.parkreldis.2021.02.003
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism
Abstract
Mutations in the glucocerebrosidase gene (GBA) encoding the lysosomal enzyme glucocerebrosidase (GCase) cause Gaucher disease (GD) and are the most commonly known genetic risk factor for Parkinson disease (PD). Ambroxol is one of the most effective pharmacological chaperones of GCase. Fourteen GD patients, six PD patients with mutations in the GBA gene (GBA-PD), and thirty controls were enrolled. GCase activity and hexosylsphingosine (HexSph) concentration were measured in dried blood and macrophage spots using liquid chromatography coupled with tandem mass spectrometry. The effect of ambroxol on GCase translocation to lysosomes was assessed using confocal microscopy. The results showed that ambroxol treatment significantly increased GCase activity in cultured macrophages derived from patient blood monocytic cell (PBMC) of GD (by 3.3-fold) and GBA-PD patients (by 3.5-fold) compared to untreated cells (p < 0.0001 and p < 0.0001, respectively) four days after cultivation. Ambroxol treatment significantly reduced HexSph concentration in GD (by 2.1-fold) and GBA-PD patients (by 1.6-fold) (p < 0.0001 and p < 0.0001, respectively). GD macrophage treatment resulted in increased GCase level and increased enzyme colocalization with the lysosomal marker LAMP2. The possible binding modes of ambroxol to mutant GCase carrying N370S amino acid substitution at pH 4.7 were examined using molecular docking and molecular dynamics simulations. The ambroxol position characterized by minimal binding free energy was observed in close vicinity to the residue, at position 370. Taken together, these data showed that PBMC-derived macrophages could be used for assessing ambroxol therapy response for GD patients and also for GBA-PD patients.
Keywords: Allosteric binding site; Ambroxol; Binding free energy; GCase; Gaucher disease; Parkinson's disease; Pharmacological chaperones.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.Int J Mol Sci. 2023 May 22;24(10):9105. doi: 10.3390/ijms24109105. Int J Mol Sci. 2023. PMID: 37240451 Free PMC article.
-
Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.J Biol Chem. 2009 Aug 28;284(35):23502-16. doi: 10.1074/jbc.M109.012393. Epub 2009 Jul 3. J Biol Chem. 2009. PMID: 19578116 Free PMC article.
-
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.Blood Cells Mol Dis. 2013 Feb;50(2):141-5. doi: 10.1016/j.bcmd.2012.10.007. Epub 2012 Nov 14. Blood Cells Mol Dis. 2013. PMID: 23158495 Free PMC article.
-
A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.Adv Protein Chem Struct Biol. 2019;114:315-339. doi: 10.1016/bs.apcsb.2018.10.002. Epub 2018 Dec 1. Adv Protein Chem Struct Biol. 2019. PMID: 30635084 Review.
-
Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.Neurochem Int. 2024 Sep;178:105774. doi: 10.1016/j.neuint.2024.105774. Epub 2024 May 24. Neurochem Int. 2024. PMID: 38797393 Review.
Cited by
-
Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.Int J Mol Sci. 2023 May 22;24(10):9105. doi: 10.3390/ijms24109105. Int J Mol Sci. 2023. PMID: 37240451 Free PMC article.
-
Autophagy Process in Parkinson's Disease Depends on Mutations in the GBA1 and LRRK2 Genes.Biochem Genet. 2025 May 19. doi: 10.1007/s10528-025-11125-z. Online ahead of print. Biochem Genet. 2025. PMID: 40388077
-
Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease.Front Neurol. 2022 Aug 12;13:971252. doi: 10.3389/fneur.2022.971252. eCollection 2022. Front Neurol. 2022. PMID: 36034282 Free PMC article. Review.
-
Do Not Miss the (Genetic) Diagnosis of Gaucher Syndrome: A Narrative Review on Diagnostic Clues and Management in Severe Prenatal and Perinatal-Lethal Sporadic Cases.J Clin Med. 2021 Oct 23;10(21):4890. doi: 10.3390/jcm10214890. J Clin Med. 2021. PMID: 34768410 Free PMC article. Review.
-
Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets.Pharmaceuticals (Basel). 2024 Dec 14;17(12):1688. doi: 10.3390/ph17121688. Pharmaceuticals (Basel). 2024. PMID: 39770531 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous